Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2004;95:1005-1011
Published online before print October 21, 2004, doi: 10.1161/01.RES.0000148635.73331.c5
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
95/10/1005    most recent
01.RES.0000148635.73331.c5v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stull, L. B.
Right arrow Articles by Marbán, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stull, L. B.
Right arrow Articles by Marbán, E.
Related Collections
Right arrow Contractile function
Right arrow Acute myocardial infarction
Right arrow Congestive
Right arrow Oxidant stress
Right arrow Animal models of human disease
(Circulation Research. 2004;95:1005.)
© 2004 American Heart Association, Inc.


Cellular Biology

Chronic Treatment With Allopurinol Boosts Survival and Cardiac Contractility in Murine Postischemic Cardiomyopathy

Linda B. Stull, Michelle K. Leppo, Luke Szweda, Wei Dong Gao, Eduardo Marbán

From the Institute of Molecular Cardiobiology (L.B.S., M.K.L., W.D.G., E.M.), Johns Hopkins University School of Medicine, Baltimore, Md; and Department of Biophysics (L.S.), Case Western Reserve University, Cleveland, Ohio.

Correspondence to Eduardo Marbán, MD, PhD, Division of Cardiology, 844 Ross Bldg, 720 Rutland Ave, Baltimore, MD 21205. E-mail marban{at}jhmi.edu

Oxidative stress is a hallmark of systemic illnesses, including heart failure. Nevertheless, the overall importance of radical production in the heart remains conjectural; is it merely a marker of illness, or can intervention alter the progression of disease? This question was addressed by blocking xanthine oxidase (XO), a superoxide-generating enzyme that is upregulated in animal models of heart failure. In a randomized prospective trial design, we administered the XO inhibitor allopurinol orally to mice that had undergone massive myocardial infarction (MI). Cardiac XO activity was elevated in untreated mice after MI; allopurinol suppressed the XO activity to levels comparable to those in sham-operated mice. Eighty-one percent of untreated mice died of advanced heart failure over 2 to 4 weeks of follow-up. Survival doubled in the allopurinol-treated mice, whereas cardiac contractile function (both in vivo and in isolated muscle) was markedly improved. Response to isoproterenol was restored to near-normal levels in the allopurinol group but was attenuated in untreated mice. Oxidative modifications to proteins were prevented in the allopurinol-treated mice. Our findings indicate that targeted blockade of just one source of oxidants, XO, impacts dramatically on the progression of postischemic cardiomyopathy in mice and prevents oxidative protein modifications.


Key Words: heart failure • mice • myocardial contraction • oxygen




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. M. Hare, B. Mangal, J. Brown, C. Fisher Jr, R. Freudenberger, W. S. Colucci, D. L. Mann, P. Liu, M. M. Givertz, R. P. Schwarz, et al.
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2301 - 2309.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. M. Shioura, D. L. Geenen, and P. H. Goldspink
Assessment of cardiac function with the pressure-volume conductance system following myocardial infarction in mice
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2870 - H2877.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. Yamamoto, K. Kataoka, T. Yamashita, Y. Tokutomi, Y.-F. Dong, S. Matsuba, H. Ogawa, and S. Kim-Mitsuyama
Role of Xanthine Oxidoreductase in the Reversal of Diastolic Heart Failure by Candesartan in the Salt-Sensitive Hypertensive Rat
Hypertension, October 1, 2007; 50(4): 657 - 662.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. Doerries, K. Grote, D. Hilfiker-Kleiner, M. Luchtefeld, A. Schaefer, S. M. Holland, S. Sorrentino, C. Manes, B. Schieffer, H. Drexler, et al.
Critical Role of the NAD(P)H Oxidase Subunit p47phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction
Circ. Res., March 30, 2007; 100(6): 894 - 903.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. P. Saliaris, L. C. Amado, K. M. Minhas, K. H. Schuleri, S. Lehrke, M. St. John, T. Fitton, C. Barreiro, C. Berry, M. Zheng, et al.
Chronic allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-adrenergic hyporesponsiveness in heart failure
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1328 - H1335.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. R. Smith, L. Barile, H. C. Cho, M. K. Leppo, J. M. Hare, E. Messina, A. Giacomello, M. R. Abraham, and E. Marban
Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens
Circulation, February 20, 2007; 115(7): 896 - 908.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. Takimoto and D. A. Kass
Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling
Hypertension, February 1, 2007; 49(2): 241 - 248.
[Full Text] [PDF]


Home page
Circ. Res.Home page
F. Ichinose, E. S. Buys, T. G. Neilan, E. M. Furutani, J. G. Morgan, D. S. Jassal, A. R. Graveline, R. J. Searles, C. C. Lim, M. Kaneki, et al.
Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Prevents Myocardial Dysfunction in Murine Models of Septic Shock
Circ. Res., January 5, 2007; 100(1): 130 - 139.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. C. Bilchick, J. G. Duncan, R. Ravi, E. Takimoto, H. C. Champion, W. D. Gao, L. B. Stull, D. A. Kass, and A. M. Murphy
Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxation-afterload and force-frequency responses and systolic function
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H318 - H325.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
B. Casadei
The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function
Exp Physiol, November 1, 2006; 91(6): 943 - 955.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler
Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. M. Zimmet and J. M. Hare
Nitroso-Redox Interactions in the Cardiovascular System
Circulation, October 3, 2006; 114(14): 1531 - 1544.
[Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Pacher, A. Nivorozhkin, and C. Szabo
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.
Pharmacol. Rev., March 1, 2006; 58(1): 87 - 114.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. J. Hajjar and J. A. Leopold
Xanthine Oxidase Inhibition and Heart Failure: Novel Therapeutic Strategy for Ventricular Dysfunction?
Circ. Res., February 3, 2006; 98(2): 169 - 171.
[Full Text] [PDF]


Home page
Circ. Res.Home page
K. M. Minhas, R. M. Saraiva, K. H. Schuleri, S. Lehrke, M. Zheng, A. P. Saliaris, C. E. Berry, K. M. Vandegaer, D. Li, and J. M. Hare
Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy
Circ. Res., February 3, 2006; 98(2): 271 - 279.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. V. Naumova, V. P. Chacko, R. Ouwerkerk, L. Stull, E. Marban, and R. G. Weiss
Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H837 - H843.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. M. Saraiva, K. M. Minhas, S. V.Y. Raju, L. A. Barouch, E. Pitz, K. H. Schuleri, K. Vandegaer, D. Li, and J. M. Hare
Deficiency of Neuronal Nitric Oxide Synthase Increases Mortality and Cardiac Remodeling After Myocardial Infarction: Role of Nitroso-Redox Equilibrium
Circulation, November 29, 2005; 112(22): 3415 - 3422.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. G. Duncan, R. Ravi, L. B. Stull, and A. M. Murphy
Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1512 - H1518.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
V. Mellin, M. Isabelle, A. Oudot, C. Vergely-Vandriesse, C. Monteil, B. Di Meglio, J. P. Henry, B. Dautreaux, L. Rochette, C. Thuillez, et al.
Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure
Eur. Heart J., August 1, 2005; 26(15): 1544 - 1550.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. M. Kittleson and J. M. Hare
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure
Eur. Heart J., August 1, 2005; 26(15): 1458 - 1460.
[Full Text] [PDF]